Back to top
more

Pacific Biosciences of California (PACB)

(Real Time Quote from BATS)

$1.32 USD

1.32
4,116,837

-0.01 (-0.75%)

Updated Aug 4, 2025 02:48 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value B Growth C Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 36% (158 out of 246)

Industry: Medical - Instruments

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

Pacific Biosciences (PACB) Jumps: Stock Rises 5.4%

by Zacks Equity Research

Pacific Biosciences (PACB) was a big mover last session, as the company saw its shares rise more than 5% on the day amid huge volumes.

    Zacks Equity Research

    Is the Options Market Predicting a Spike in Pacific Biosciences (PACB) Stock?

    by Zacks Equity Research

    Investors need to pay close attention to Pacific Biosciences (PACB) stock based on the movements in the options market lately.

      Zacks Equity Research

      Pacific Biosciences' Sequel Sees Solid Q2, Competition Rife

      by Zacks Equity Research

      Pacific Biosciences (PACB) gains from solid presence in Asia; competition likely to mar results.

        Zacks Equity Research

        Pacific Biosciences (PACB) Loss In Line With Estimates in Q2

        by Zacks Equity Research

        Strong performance in Product revenues boosts Pacific Biosciences (PACB) in Q2. Sequel order improves year over year.

          Zacks Equity Research

          Pacific Biosciences of California (PACB) Reports Q2 Loss, Misses Revenue Estimates

          by Zacks Equity Research

          Pacific Biosciences (PACB) delivered earnings and revenue surprises of 0.00% and -8.72%, respectively, for the quarter ended June 2018. Do the numbers hold clues to what lies ahead for the stock?

            Zacks Equity Research

            What's in Store for Pacific Biosciences' (PACB) Q2 Earnings?

            by Zacks Equity Research

            Pacific Biosciences' (PACB) flagship Sequel System is likely to drive Q2 results; competition is a headwind.

              Zacks Equity Research

              Moving Average Crossover Alert: Pacific Biosciences of California (PACB)

              by Zacks Equity Research

              Pacific Biosciences of California, Inc. (PACB) is looking like an interesting pick from a technical perspective

                Nabaparna Bhattacharya headshot

                Genomics Market Gains Momentum: 3 DNA Stocks in Focus

                by Nabaparna Bhattacharya

                Here we discuss about how Genomics creates opportunities in MedTech for investors who are keen on putting money in the healthcare space.

                  Zacks Equity Research

                  Pacific Biosciences to Gain From New Genome Sequencing Tools

                  by Zacks Equity Research

                  Pacific Biosciences' (PACB) new multiplexing kit to make genome sequencing faster and cost-effective.

                    Zacks Equity Research

                    Why Is Pacific Biosciences (PACB) Down 6.7% Since its Last Earnings Report?

                    by Zacks Equity Research

                    Pacific Biosciences (PACB) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

                      Zacks Equity Research

                      Pacific Biosciences (PACB) Loss Wider Than Expected in Q1

                      by Zacks Equity Research

                      Pacific Biosciences (PACB) Q1 earnings and revenues miss estimates; Sequel orders rise.

                        Zacks Equity Research

                        Can Core Unit Drive Pacific Biosciences' (PACB) Q1 Earnings?

                        by Zacks Equity Research

                        Pacific Biosciences gains ground on solid Sequel Growth, while shrinking service revenues raise concern.

                          Zacks Equity Research

                          Pacific Biosciences Gains as HudsonAlpha Picks Sequel System

                          by Zacks Equity Research

                          Pacific Biosciences (PACB) sees increasing use of Sequel Sequencing System in pediatric and plant biologic case studies.

                            Zacks Equity Research

                            Pacific Biosciences Unveils New Version of Sequel Software

                            by Zacks Equity Research

                            Pacific Biosciences (PACB) enhances performance and cost-effectiveness of the Sequel System.

                              Zacks Equity Research

                              Pacific Biosciences (PACB) Down 15.6% Since Earnings Report: Can It Rebound?

                              by Zacks Equity Research

                              Pacific Biosciences (PACB) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

                                Zacks Equity Research

                                Are Options Traders Betting on a Big Move in Pacific Biosciences (PACB) Stock?

                                by Zacks Equity Research

                                Surging implied volatility makes Pacific Biosciences (PACB) stock lucrative to the option traders.

                                  Zacks Equity Research

                                  Pacific Biosciences (PACB) Q4 Loss Narrows, Consumables Up

                                  by Zacks Equity Research

                                  Pacific Biosciences' (PACB) consumable revenue platform proves a vital growth-driver in Q4. Sales momentum in China remains robust.

                                    Zacks Equity Research

                                    Options Traders Expect Huge Moves in Pacific Biosciences (PACB) Stock

                                    by Zacks Equity Research

                                    Pacific Biosciences (PACB) needs investors to pay close attention to the stock based on moves in the options market lately.

                                      Zacks Equity Research

                                      What's in Store for Pacific Biosciences (PACB) in Q4 Earnings?

                                      by Zacks Equity Research

                                      Pacific Biosciences (PACB) is likely to witness year-over-year decline in product revenues.

                                        Zacks Equity Research

                                        Pacific Biosciences Hurt by Competition in Niche Markets

                                        by Zacks Equity Research

                                        Pacific Biosciences (PACB) faces cutthroat competition in the niche space. Also, sluggishness in the European markets is a concern.

                                          Zacks Equity Research

                                          Pacific Biosciences (PACB) Q3 Loss Narrower Than Estimated

                                          by Zacks Equity Research

                                          Pacific Biosciences (PACB) witnesses solid contribution from the Instrument and Consumable revenue platforms. Consumable revenue growth was driven by higher installed base of instruments.

                                            Zacks Equity Research

                                            Pacific Biosciences, Bluebee Team Up for De Novo Sequencing

                                            by Zacks Equity Research

                                            With increasing demand for SMRT sequencing in the genomics community, both Pacific Biosciences (PACB) and partner Bluebee expect a huge customer adoption of integrated de novo assembly pipeline.

                                              Zacks Equity Research

                                              Pacific Biosciences (PACB) Posts Wider-than-Expected Q2 Loss

                                              by Zacks Equity Research

                                              Pacific Biosciences (PACB) posted a dull quarter with revenues declining in Q2. However, the company continues to anticipate 35% to 45% growth in product and service revenues for the year.

                                                Zacks Equity Research

                                                Pacific Biosciences (PACB) Prices Offering of Common Stock

                                                by Zacks Equity Research

                                                Pacific Biosciences of California, Inc. (PACB) recently announced that it has priced its underwritten public offering of 15.4 million shares of its common stock.

                                                  Zacks Equity Research

                                                  Pacific Biosciences (PACB) Q1 Loss Wider than Estimated

                                                  by Zacks Equity Research

                                                  Pacific Biosciences of California Inc. (PACB) reported a loss of 26 cents per share in the first quarter of 2017. The figure is 3 cents wider than the Zacks Consensus Estimate.